WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has secured priority review from the U.S. Food and Drug Administration for its experimental treatment of microcystic lymphatic malformations, putting the Wayne-based biotechnology company on a potential path to its first commercial drug launch in 2027.
The FDA accepted Palvella’s new drug application for QTORIN 3.9% rapamycin anhydrous gel and established a February 28, 2027, target date for its regulatory decision, the company reported.
If approved, the topical treatment would become the first FDA-approved therapy for microcystic lymphatic malformations, a rare, lifelong disorder affecting an estimated 30,000 or more diagnosed children and adults in the United States.
The regulatory decision represents a significant commercial milestone for Palvella, which is preparing to transition from a clinical-stage drug developer to a company marketing its own treatments.
The application is supported primarily by the Phase 3 SELVA trial, which met all six prespecified efficacy endpoints with statistical significance.
Among participants aged 6 and older who completed the efficacy evaluation period, 95% demonstrated improvement on the study’s primary endpoint, the microcystic lymphatic malformation Investigator Global Assessment.
All six efficacy endpoints achieved p-values below 0.001, indicating that the observed treatment effects were statistically significant.
Palvella also reported that QTORIN rapamycin was well tolerated during the trial, with no drug-related serious adverse events.
Systemic rapamycin concentrations remained below 2 nanograms per milliliter at all measured time points for all participants, suggesting limited systemic exposure during treatment.
The FDA application includes additional Phase 2 clinical results, published research and evidence involving the off-label use of rapamycin in patients with microcystic lymphatic malformations.
QTORIN rapamycin has received Breakthrough Therapy, Fast Track and Orphan Drug designations from the FDA. Its development has also received grant funding from the agency’s Office of Orphan Products Development.
Priority Review shortens the FDA’s standard review timetable for qualifying applications but does not guarantee approval.
Microcystic lymphatic malformations are caused by abnormalities in lymphatic vessel development associated with dysregulation of the PI3K/mTOR signaling pathway.
The condition can produce malformed vessels that protrude through the skin, resulting in persistent leakage, bleeding, recurrent infections and impaired physical function.
Existing treatment approaches include surgery, sclerotherapy and laser procedures, although recurrence and the need for repeated interventions can limit their effectiveness.
Systemic medications targeting the PI3K/mTOR pathway may also present long-term safety and tolerability challenges, particularly for children.
QTORIN rapamycin is designed to deliver treatment directly to affected skin through a topical formulation targeting the biological pathway associated with the disease.
Palvella plans a standalone U.S. commercial launch during the first half of 2027, contingent on regulatory approval.
The company has established commercial leadership, deployed medical science liaisons across the United States and developed a patient services organization to support a potential introduction.
Current preparations include engagement with treating specialists, patient identification, insurance coverage and reimbursement planning, and patient support services.
Palvella founder and Chief Executive Officer Wes Kaupinen described the FDA’s acceptance of the application and its priority review designation as important steps toward commercialization.
“With compelling Phase 3 SELVA results and a February 28, 2027 PDUFA target action date, we believe we are closer than ever to delivering on that mission,” Kaupinen stated.
Beyond the initial indication, Palvella is developing QTORIN rapamycin for cutaneous venous malformations and clinically significant angiokeratomas.
The company is also advancing QTORIN pitavastatin for disseminated superficial actinic porokeratosis, another rare skin disorder.
Those programs are intended to extend Palvella’s topical drug delivery platform into additional diseases with limited treatment options.
The February FDA decision will determine whether Palvella can proceed with its planned U.S. launch of QTORIN rapamycin for microcystic lymphatic malformations.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.